---
title: "Imugene Seeks ASX Quotation for 27.6 Million New Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296971491.md"
description: "Imugene Limited has applied for the quotation of approximately 27.6 million new ordinary shares on the ASX, with an issue date set for August 25, 2026. This move supports capital raising for its biotechnology programs and clinical development in immuno-oncology. While potentially dilutive to existing shareholders, it aims to strengthen the company's market position. The latest analyst rating is a Buy with a A$0.25 price target."
datetime: "2026-08-26T01:32:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296971491.md)
  - [en](https://longbridge.com/en/news/296971491.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296971491.md)
generator: "portal-rs"
---

# Imugene Seeks ASX Quotation for 27.6 Million New Shares

Imugene ( (AU:IMU) ) just unveiled an announcement.

Imugene Limited has applied for quotation of 27,578,949 ordinary fully paid shares on the ASX, with an issue date of August 25, 2026. The new securities are tied to previously announced transactions, indicating a follow-through on capital-raising or corporate actions disclosed in earlier filings.

The additional share quotation underscores Imugene’s continued use of equity markets to fund its biotechnology programs and operations. This move may slightly dilute existing shareholders but supports the company’s ability to finance clinical development, potentially strengthening its position in the competitive immuno-oncology landscape over the medium term.

The most recent analyst rating on (AU:IMU) stock is a Buy  
 with a A$0.25 price target.  
 To see the full list of analyst forecasts on Imugene stock,  
 see the AU:IMU Stock Forecast page. 

**More about Imugene**

Imugene Limited is an Australian biotechnology company listed on the ASX, focused on developing novel immunotherapies. The company operates in the biopharmaceutical sector, with its primary activities centered on research and development of cancer treatments leveraging immune-oncology platforms.

Imugene targets global oncology markets, aiming to advance its pipeline of clinical and preclinical assets. As a listed entity under the ticker IMU, it routinely accesses capital markets to support ongoing development and commercialisation efforts in highly competitive cancer therapy segments.

**Average Trading Volume:** 3,333,487

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** A$40.16M

Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [IMU.AU](https://longbridge.com/en/quote/IMU.AU.md)

## Related News & Research

- [Imugene shareholders back capital-raising resolutions at extraordinary meeting](https://longbridge.com/en/news/296287728.md)
- [Imugene applies for ASX quotation of additional ordinary shares](https://longbridge.com/en/news/281992436.md)
- [AMA Group Seeks ASX Quotation for 757,685 New Ordinary Shares](https://longbridge.com/en/news/297842777.md)
- [India's NSE eyes Sep 21-week listing after regulator clears IPO, sources say](https://longbridge.com/en/news/298101548.md)
- [Rubicon Water issues new shares and lodges cleansing notice to ASX](https://longbridge.com/en/news/297599873.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**